Cargando…

Antibody engineering to develop new antirheumatic therapies

There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment...

Descripción completa

Detalles Bibliográficos
Autor principal: Isaacs, John D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714093/
https://www.ncbi.nlm.nih.gov/pubmed/19490600
http://dx.doi.org/10.1186/ar2594